with

Monitoring and Managing Toxicities Associated

Immune-Checkpoint Inhibitors

Dr. Melinda S. Weber DNP, APN, AOCN, C

Director of Care Transformation & Charge APN Skin & Sarcoma Division

John Theurer Cancer Center Hackensack Meridian Health









Speaker for Bristol Myers Squibb








- 1. Review the current FDA-Approved for Immune Checkpoint Inhibitors (ICI) therapy in Oncology & **Mechanism of Action**
- 1. <u>Discuss Principles/Process & Grading of Immune-Mediated Adverse Reactions/(IMARS)/ Immune-</u> Mediated Adverse Events, (irAE's) with emphasis on Early Recognition
- 3. **Implement Prompt Evidence-Based Interventions to Treat IMARS/irAE's**
- and Mortality


4. <u>Discuss Principles of Patient Education and Supportive Patient Care Interventions to minimize Morbidity</u>





Mechanism of Action of Immunotherapies





Mechanism of Action of Immunotherapies

STEPS 1-3: INITIATING AND PROPAGATING ANTICANCER IMMUNITY¹

- Oncogenesis leads to the expression of neoantigens that can be captured by dendritic cells
- <u>Dendritic cells can present antigens to T cells</u>, priming and activating cytotoxic T cells to attack the cancer cells


STEPS 4-5: ACCESSING THE TUMOR¹

 Activated T cells travel to the tumor and infiltrate the tumor microenvironment

STEPS 6-7: CANCER-CELL RECOGNITION AND INITIATION OF CYTOTOXICITY¹

- Activated T cells can recognize and kill target cancer cells
- Dying cancer cells release additional cancer antigens, propagating the cancer immunity <u>cycle</u>





Mechanism of Action of Immunotherapies

STEP 3: PRIMING AND ACTIVATION

- · CD28/B7.1
- · CD137/CD137L
- · OX40/OX40L*
- · CD27/CD70*
- HVEM
- GITR
- IL-2*
- IL-12

CTLA4/B7.1

- PD-L1/B7.1*
- PD-L1/PD-1*
- Prostaglandins
- Active cytotoxic T cell STEP 3 Dendritic cell • IL-10 STEP 2 • IL-13 STEP 1 Cancer antigens.

STEP 2: CANCER ANTIGEN PRESENTATION

- TNFα
- IL-4
- IL-1
- ·IFNα
- CD40L/CD40*
- CDN
- ATP
- HMGB1
- TLR

STEP 1: RELEASE OF CANCER CELL ANTIGENS

 Immunogenic Tolergenic cell death cell death


Tumor apoptosis

STEP 7: KILLING OF CANCER CELLS

- IFNγ
- T-cell granule
 PD-L1/PD-1* content

STEP 4: TRAFFICKING OF T CELLS TO TUMORS

• CX3CL1 • CXCL9 • CXCL10 • CCL5



- IDO*
- TGFβ
- BTLA
- · PD-L1/B7.1*

- LAG-3
- Arginase
- MICA-MICB
- B7-H4
- VISTA
- TIM-3/phospholipids



Current List of FDA-Approved Immune Checkpoint Inhibitors

5.Durvalumab (IMFINZI)- is a programmed death-ligand 1 (PD-L1) blocking antibody/Multiple Indications

1.Atezolizumab (TECENTRIQ)- is a programmed death-ligand 1 (PD-L1) blocking antibody/Multiple Indications

2. Avelumab (BAVENCIO)-is a programmed death-ligand 1 (PD-L1) blocking antibody/Multiple Indications

3. Cemiplimab-rwlc (LIBTAYO)- is a programmed death receptor-1 (PD-1) blocking antibody/Multiple Indications

4. Dostarlimab-gxly(JEMPERLI)-is a programmed death-ligand 1 (PD-L1) blocking antibody/Multiple Indications











Current List of FDA-Approved Immune Checkpoint Inhibitors

- 5. Ipilimumab (YERVOY)- is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody/Multiple Indications
- **6. Nivolumab (OPDIVO)** is a programmed death receptor-1 (PD-1) blocking antibody/Multiple Indications ***Also available in combination as **OPDUALAG, (nivolumab and relatinib-rmbw**) -a lymphocyte activation gene-3, (LAG) blocking antibody. (2022)
- **7. Pembrolizumab (KEYTRUDA)** is a programmed death receptor-1 (PD-1) blocking antibody/Multiple Indications
- **<u>8. Retifanlimab-dlwr (ZYNYZ)</u>**-is a programmed death receptor-1 (PD-1) blocking antibody for the treatment of metastatic or recurrent locally advanced adult Merkel cell carcinoma
- **<u>9. Tremelimumab (Imjuno)-</u>**is a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4)-blocking antibody. Indicated for use with durvalumab, for adult patients with unresectable hepatocellular carcinoma





Strategies for Early Recognition & Prompt Interventions for Immunotherapy-Related Toxicity

- Status
- Comprehensive Baseline Physical Assessment
- Social Determinants of Health
- Financial Toxicity
- Gravity of Current Malignancy
- Comprehensive Patient & Significant Other(s) Education

NCCN. Clinical Practice Guidelines in Oncology. Management of immuno-related toxicities Accessed 2024; Walker S et al. Guide to Cancer immunotherapy. 2018.

• Comprehensive Baseline Assessment of the Patient's Current Emotional, Physical and Spiritual









Common Terminology Criteria for Adverse Events (CTCAE) v 5.0 Publish Date: November 27, 2017

- **Grade 1:** Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated.
- **Grade 2:** Moderate; minimal, local or noninvasive intervention indicated; limiting age appropriate instrumental ADL.
- **Grade 3:** Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL. **<u>Grade 4</u>**: Life-threatening consequences; urgent intervention indicated. **Grade 5:** Death related to AE.

Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, 2017.

Strategies for Early Recognition & Prompt Interventions for Immunotherapy-Related Toxicity







Diarrhea

- **Grade 1**: Increase of <4 stools per day over baseline; mild increase in ostomy output compared to baseline
- **Grade 2**: Increase of 4 6 stools per day over baseline; moderate increase in ostomy output compared to baseline; limiting instrumental ADL
- **Grade 3:** Increase of >=7 stools per day over baseline; hospitalization indicated; severe increase in ostomy output compared to baseline; limiting self care ADL
- **<u>Grade 4</u>**: Life-threatening consequences; urgent intervention indicated
- **Grade 5:** Death related to AE.
- Common Terminology Criteria for Adverse Events (CTCAE) v5.0 Publish Date: November 27, 2017.

Strategies for Early Recognition & Prompt Interventions for Immunotherapy-Related Toxicity





Strategies for Early Recognition & Prompt Interventions for Immunotherapy-Related Toxicity

- Immune-Mediated Adverse Reactions (IMARS) can occur in <u>any organ system</u>
- IMARS have varying onset and can appear within the first 1-2 weeks, the first 12 weeks, vary in every patient
- IMARS can recur 22+ months after the completion of I-O therapy
- Each I-O manufacturer reports varying occurrence percentages of each of IMARS, their onset and duration

NCCN. Clinical Practice Guidelines in Oncology. Management of immuno-related toxicities Accessed 2024; Walker S et al. *Guide to Cancer immunotherapy*. 2018.

Adverse Reactions vs IMARS-Must Differentiate these toxicities! Chemo-related? Radiation therapy related? Or from Immuno-Oncology Agents?







Strategies for Early Recognition & Prompt Interventions for Immunotherapy-Related Toxicity

Adverse Reactions vs IMARS?

Must Differentiate other Oncologic Therapy Related Toxicities & Benign Disease Issues!

Chemotherapy-related? I-O Combination Regimens? **Radiation therapy related? Concurrent I-O? Disease Progression? Comorbidities**?

Or from Immuno-Oncology Agents?

NCCN. Clinical Practice Guidelines in Oncology. Management of immuno-related toxicities Accessed 2024; Walker S. et al. *Guide to Cancer immunotherapy*. 2018.







- fatigue/asthenia, musculoskeletal pain
- decreased appetite, diarrhea, nausea/vomiting, pyrexia
- cough, dyspnea, constipation, abdominal pain
- pruritus/rash, peripheral neuropathy
- mucosal inflammation, alopecia, and stomatitis

NCCN. Clinical Practice Guidelines in Oncology. Management of immuno-related toxicities. Accessed 2024.

Strategies for Early Recognition & Prompt Interventions for Immunotherapy-Related Toxicity

Immune-Mediated Adverse Reactions (IMARS) **More Common Symptoms:**







- Pneumonitis
- Colitis
- Hepatitis
- Encephalitis
- thyroid, pituitary-gonadal, pituitary-adrenal systems-visual disturbance, confusion, memory loss, hallucinations, Adrenal insufficiency, Hyper/Hypothyroidism, Type 1 diabetes mellitus
- Endocrinopathies- Hypophysitis-inflammation of the pituitary gland-pituitary-hypothalamic, pituitary-• Dermatologic adverse reactions including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN)
- Nephritis and Renal Dysfunction
- Solid Organ Transplant Rejection
- Infusion-Related Reactions
- Embryo-Fetal toxicity

NCCN. Clinical Practice Guidelines in Oncology. Management of immuno-related toxicities Accessed 2024.

Strategies for Early Recognition & Prompt Interventions for Immunotherapy-Related Toxicity **Immune-Mediated Adverse Reactions on Organ Systems Include:**







Adverse Reaction Severity & Dose Modification

- **Colitis:**

Grade 2 diarrhea or colitis- Withhold dose till return to baseline **Grade 3 diarrhea or colitis**-Withhold dose when I-O administered as a single agent Grade 4 diarrhea or colitis- Permanently discontinue

Pneumonitis:

Grade 2 pneumonitis- Withhold dose till return to baseline Grade 3 or 4 pneumonitis - Permanently discontinue

NCCN. Clinical Practice Guidelines in Oncology. Management of immuno-related toxicities Accessed 2024.

 Each Manufacturer has IMAR Guidelines for Severity, Dose Modification and Discontinuation The Range of IMAR Onset and Duration is Different for Each I-O Agent







- Patient and Caregiver Education that is Understood is Key!
- Social Determinants of Health Considerations are CRITICAL!!!
- Through Informed consent is Critical to Patient Participation and Understanding
- Comprehensive assessment of reported IMAR. Related to I-O or not?
- Grade the IMAR and call HCP STAT
- Consider Comorbidities in all aspects of interventions e.g. The Geriatric Patient

Unsafe living conditions? Might require emergency hospitalization

NCCN. Clinical Practice Guidelines in Oncology. Management of immuno-related toxicities Accessed 2024.





- Corticosteroids
- Infliximab (Remicade)
- Mycophenolate mofetil (Cellcept)
- Intravenous Immunoglobulin Therapy (IVIG)
- Rituximab (Rituxan)
- Methotrexate
- Cyclophosphamide
- Plasmapheresis-has also been used

NCCN. Clinical Practice Guidelines in Oncology. Management of immuno-related toxicities Accessed 2024.

Pharmacological Interventions

Use Approved Supportive Therapies as per HCP & Follow Institutional Policies





Pharmacological Interventions

- **Corticosteroids**-Have variable effects on all T lymphocytes. Corticosteroids enter the cellular membrane and attach to the glucocorticoid receptor. Corticosteroids then bind to/interrupts DNA. This binding them suppresses inflammation by:
- Reducing the number of T cells in circulation, especially immature CD4+ T cells
- Reduces memory T cells, T helper type 17+ (Th17+) T cells, and CD8+ effector T cells,.
- Infliximab (Remicade) Is a monoclonal antibody that binds to Tumor Necrosis Factor-α and disrupts the proinflammatory cascade.
- induction of TNF-producing cells such as activated monocytes and T lymphocytes.

• <u>High dose corticosteroids</u>, (doses >1 mg/kg per day in children or >40 mg daily in adults), rapidly destroys most circulating T cells by inhibiting IL2-responsible for T cell growth, impairs release of T cells from the lymph system

 Once TNF-a is blocked, downregulation of local and systemic pro-inflammatory cytokines (i.e. IL-1, IL-6), occurs. • This reduces and inhibits lymphocyte and leukocyte migration to sites of inflammation and induces cell death of







- Mycophenolate mofetil (MMF, CellCept(R))- is a precursor of mycophenolic acid (MPA). It inhibits inosine monophosphate dehydrogenase (IMPDH). T and B-lymphocytes need this pathway to survive. MPA is incredibly lethal to lymphocytes than on other cell types.
- system, not all of which are completely understood.
- notably, expansion of the regulatory T cell population.
- Additionally, IVIG induces anti-inflammatory cytokines from innate cells and leads to decreased macrophage responsiveness to interferon.

Pharmacological Interventions

• Intravenous Immunoglobulin Therapy (IVIG)-IVIG has many actions and competitive interactions in the human immune

• IVIG inactivates T-cells by competing for and interrupting their interaction of binding with antigen presenting cells and







Pharmacological Interventions

- <u>Rituximab (Rituxan) Is a monoclonal antibody who's mechanisms of action are still not fully understood.</u>
- In IMAR's, Rituxan binds to the CD4+ receptor in T's cells leading to apoptosis.
- Research on rheumatoid arthritis led to research in use with IMAR's in checkpoint inhibitor therapies.
- **Methotrexate-Is** an antifolate antimetabolite cancer chemotherapeutic agent.
- causes depriviation of a form of folic acid, that in turn prevents DNA synthesis, thereby being cytotoxic.
- IMAR's and autoimmune diseases because it inhibits the enzyme AICAR transformylase.
- This lack of enzyme suppresses adenosine and guanine metabolism which leads to Adenosine accumulation. Adenosine is a powerful anti-inflammatory that suppresses T-cells.
- damages normal DNA production and inhibiting protein synthesis, leading to cell death.
- Additionally, Cyclophosphamide's cytotoxicity targets T cells, and specific damage to T regs.

• However, methotrexate has a different mechanism of action in the treatment of IMAR's. Methotrexate is used in

• Cyclophosphamide- is a non-cell cycle specific cancer chemotherapy. It is a type of nitrogen mustard drug that





Discuss Principles of Patient Education and Supportive Patient Care Interventions to Minimize Morbidity and Mortality

Potential for untoward morbidity and mortality related to I-O induced (IMARS) Assessment/Planning/Implementation & Evaluation Include:

- Reinforcement of evidence-based individualized patient education concerning IMARS.
- Know your patient's coping mechanisms & support systems!
- Urge STAT provider notification of any untoward reaction
- Urge compliance of all IMAR interventions and supportive teaching compliance

NCCN. Clinical Practice Guidelines in Oncology. Management of immuno-related toxicities Accessed 2024; Walker S et al. *Guide to Cancer immunotherapy*. 2018.







Discuss Principles of Patient Education and Supportive Patient Care Interventions to Minimize Morbidity and Mortality

Potential for untoward morbidity and mortality related to I-O induced (IMARS) Assessment/Planning/Implementation & Evaluation Include:

- Provide on-going ECOG status, vital signs monitoring, laboratory/radiological assessments
- Provide ongoing physical, emotional and spiritual assessments
- Provide ongoing healthcare and supportive care interventions
- Ongoing assessment of patient compliance and participation and potential IMARS

NCCN. Clinical Practice Guidelines in Oncology. Management of immuno-related toxicities Accessed 2024; Walker S et al. *Guide to Cancer immunotherapy*. 2018.







What Does the Future Hold?





• IL-10

• IL-4

• IL-13

- · CD28/B7.1
- CD137/CD137L
- · OX40/OX40L*
- · CD27/CD70*
- HVEM
- GITR
- IL-2*
- IL-12

STEP 2: CANCER ANTIGEN PRESENTATION

- $\cdot TNF\alpha$
- IL-1
- ·IFNα
- · CD40L/CD40*
- CDN
- ATP
- HMGB1
- TLR

- CTLA4/B7.1
- PD-L1/B7.1*
- PD-L1/PD-1*
- Prostaglandins
 - STEP 3

Dendritic cell STEP 2

Cancer

antigens

STEP 1

Active

T cell

cytotoxic


Tumor apoptosis

STEP 1: RELEASE OF CANCER CELL ANTIGENS

 Tolergenic Immunogenic cell death cell death

- IFNγ
- T-cell granule content

STEP 4: TRAFFICKING OF T CELLS TO TUMORS



STEP 7: KILLING OF CANCER CELLS

· PD-L1/B7.1*

- · PD-L1/PD-1*
- · IDO*
- TGFβ
- BTLA

- TIM-3/phospholipids
- MICA-MICB

Arginase

• B7-H4

• LAG-3

VISTA





Do You Have Any Questions?

Melinda.weber@hmhn.org

John Theurer Cancer Center

Hackensack Meridian Health



References

- Abbas, A. K., Lichtman, A.H. & Pillai, S. (2012). Cellular and molecular Immunology. 7th ed. *Nature Reviews: Drug Discovery*, 14, 603-622. Retrieved from http://www.nature.com/
- Adams, J.L., Smothers, J., Simivasan, R. & Hoos, A. (2015). Big opportunities for small molecules in immuno-oncology. Nature Reviews: Drug Discovery, 14, 603-622. Retrieved from http: <u>www.nature.com</u>
- Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK554446/
- Pharmaceuticals LP; 2021.Retrieved from https://www.imfinzihcp.com/
- 2022. Retrieved from https://www.imfinzihcp.com/
- Bristol-Myers Squibb. (2022). Highlights of prescribing information: OPDUALAG Copyright © 2022 Bristol-Myers Squibb Company. Retrieved from https://www.opdualag.com/
- Bristol-Myers Squibb. (2016). Immuno-Oncology: Pathways that modulate the adaptive immune response. Retrieved from http://www.immunooncologyhcp.bmsinformation.com

Philadelphia: Elsevier Adams, J.L., Smothers, J., Simivasan, R. & Hoos, A. (2015). Big opportunities for small molecules in immuno-oncology.

Arumugham VB, Rayi A. Intravenous Immunoglobulin (IVIG) [Updated 2023 Jul 3]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls

AstraZeneca Pharmaceuticals LP. (2022). Imfinzi (durvalumab) package insert. Cambridge, England: AstraZeneca UK Limited; AstraZeneca

AstraZeneca Pharmaceuticals LP. (2022). Imjudo (tremelimumab-actl) package insert. Wilmington, DE; AstraZeneca Pharmaceuticals LP;












- Bristol-Myers Squibb. (2024). Highlights of prescribing information: Opdivo Copyright © 2014 Bristol-Myers Squibb Company. Retrieved from https://www.opdivo.com/
- Bristol-Myers Squibb. (2024). Highlights of prescribing information: Yervoy Copyright © 2011 Bristol-Myers Squibb Company. Retrieved from https://www.yervoy.com/
- Genentech Oncology. (2017). Research cancer immunotherapy: Science is changing the score. Retrieved from http://www.researchcancerimmunotherapy.com
- Genentech Oncology. (2024). Tecentriq (atezolizumab) package insert. South San Francisco, CA: Genentech, Inc.; 2016. Retrieved from: <u>https://www.tecentriq.com</u>
- from: https://www.ncbi.nlm.nih.gov/books/NBK564374/
- Available from: https://www.ncbi.nlm.nih.gov/books/NBK556114/
- Incyte Corporation. (2024). Highlights of prescribing information: ZYNYZ® (retifanlimab-dlwr) package insert. Wilmington DE. (2024) Retrieved from <u>http://www.zynyz.com</u>
- Karp, Daniel D., Falchook, G.S. & Lim, JoAnn, D. (2023). Handbook of targeted cancer therapy and immunotherapy 3rd ed. Pittsburgh. Wolters Kluwer.

References

Hanif N, Anwer F. Rituximab. [Updated 2024 Feb 28]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available

Hanoodi M, Mittal M. Methotrexate. [Updated 2023 Aug 16]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-.





- association with clinical response. Arthritis Rheum. 2013 Nov;65(11):2783-90. doi: 10.1002/art.38107. PMID: 23918413.
- Merck KGaA; EMD Serono, Inc; and Pfizer Inc. (2020). Bavencio (avelumab) package insert. Darmstadt, Germany: Merck KGaA; EMD Serono, Inc.; and Pfizer Inc.; 2017.Retrieved from https://www.bavencio.com

Merck Sharp & Dohme Corp. (2024). Highlights of prescribing information: KEYTRUDA(pembrolizumab) Copyright ® 2014 Merck prescribing information.Retrieved from https://www.keytruda.com/

National Comprehensive Cancer Network. (2024). NCCN Guidelines Version 1.2024-December 7, 2023. Management of immuno-related toxicities. National Comprehensive Network Inc. Retrieved from: https://www.nccn.org/guidelines

National Comprehensive Cancer Network. (2024). NCCN Guidelines for Patients Immunotherapy Side Effects, Immune Checkpoint Inhibitors. National Comprehensive Cancer Network Inc. Retrieved from: https://www.nccn.org/guidelines

Ogino MH, Tadi P. Cyclophosphamide. [Updated 2023 Jul 3]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK553087/

Regeneron Pharmaceuticals Inc. (2024). Regeneron Pharmaceuticals, Inc. (cemiplimab-rwlc) LIBTAYO® package insert. Regeneron Pharmaceuticals, Inc. / sanofi-aventis U.S. LLC. All rights reserved. (2018). Retrieved from: <u>https://www.libtayo.com</u>

References

Mélet J, Mulleman D, Goupille P, Ribourtout B, Watier H, Thibault G. Rituximab-induced T cell depletion in patients with rheumatoid arthritis:





- U.S. Department of Health & Human Services, National Institutes of Health National Cancer institute (2017). Common Terminology Criteria for Adverse Events. Version 5.0 (NCI CTCAE v5). Retrieved from http: <u>https://evs.nci.nih.gov</u>
- Walker, S & Dunphy, E. P. (2018). Guide to cancer immunotherapy. Pittsburgh: Oncology Nursing Society.
- Zhixuan QU. 2023. Investigating Conventional and Novel Methods for Treatment of Cancer. In 12th International Conference on Bioscience, Biochemistry and Bioinformatics (ICBBB 2023), January 13-16, 2023, Tokyo, Japan. https://doi.org/10.1145/3586139.3586154

References







Slide Header

